Outlook Therapeutics (OTLK) Receivables - Other (2015 - 2016)

Outlook Therapeutics (OTLK) reported Receivables - Other of $43350.0 for Q2 2016, little changed quarter-over-quarter from $43187.0 in Q1 2016.

Outlook Therapeutics (OTLK) Receivables - Other (2015 - 2016) Analysis & Trends

Outlook Therapeutics (OTLK) has 2 years of Receivables - Other data on file, last reported at $43350.0 in Q2 2016.

Receivables - Other for Q2 2016 came in at $43350.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2016 was $43350.0 (changed N/A YoY), and the FY2015 annual result was $117506.0, changed N/A from the prior year.
Receivables - Other steadied at $43350.0 in Q2 2016 per OTLK's latest filing, from $43187.0 in the prior quarter.
Over five years, Receivables - Other peaked at $117506.0 in Q3 2015 and troughed at $43187.0 in Q1 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn
9	Abivax	94.37 Bn	94.37 Bn	-
10	Outlook Therapeutics	51.56 Mn	43.81 Mn	-21,888.00

Download Data